Viridian Therapeutics, Inc.VRDNNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+47.1%
5Y CAGR+39.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+47.1%/yr
vs +34.6%/yr prior
5Y CAGR
+39.1%/yr
Recent acceleration
Acceleration
+12.5pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
5.2x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $433.08M | +44.7% |
| 2024 | $299.34M | +17.5% |
| 2023 | $254.76M | +87.2% |
| 2022 | $136.08M | +64.6% |
| 2021 | $82.69M | -0.5% |
| 2020 | $83.13M | +79.0% |
| 2019 | $46.44M | +12.0% |
| 2018 | $41.47M | +35.8% |
| 2017 | $30.54M | +191.8% |
| 2016 | $10.46M | - |